Table 1.
Ref.
|
Year
|
Hematopoietic stem cells
|
Transplantation
|
||||
Donor
|
Source
|
Lineage
|
Cell dose
|
Route
|
Volume (µL)
|
||
Lee et al[9] | 2021 | Mice (C57BL/6) | BM | NC | 1 × 107 | IV | NR |
Huang et al[10] | 2021 | Human | UCB | MNC | 1 × 107 | IV; IB | 200; NR |
Yin et al[8] | 2020 | Human | UCB | CD34+ | 2.5 × 103; 5 × 103; 1 × 104; 2 × 104 | IV; IB | NR; 10 |
Choi et al[11] | 2020 | Mice (C57BL/6) | BM | NC | 1 × 107 | IV | 200 |
Trento et al[12] | 2017 | Mice (C57BL/6 CD45.1) | BM | NC | 2 × 106 | IV | NR |
Abbuehl et al[13] | 2017 | Mice (FVB Actin-GFP) | BM | NC | 5 × 106 | IV | 100 |
Kim et al[14] | 2016 | Mice (C57BL/6J-Pep3b-Ly5.1 Pep3b) | BM | NC | 2 × 104 | NR | NR |
Futrega et al[15] | 2016 | Human | UCB | CD34+ | 5 × 104 | IV; IB | 100; 10 |
van der Garde et al[16] | 2015 | Human | UCB | CD34+ | 2 × 105 | IV | NR |
Fernández-García et al[17] | 2015 | Mice (P3D2F1 H2b/d CD45.1) | BM | LSK | 1.5 × 104 | NR | NR |
Chen et al[18] | 2015 | Mice (C57BL/6) | BM | NC | 5 × 106 | IV | NR |
Chen et al[19] | 2014 | Human | UCB | CD34+ | 1 × 105 | IV | NR |
Wu et al[20] | 2013 | Human | UCB | NC | 1 × 106 | IV | 250 |
Lim et al[21] | 2013 | Human | UCB | MNC | 1 × 107 | IV | 200 |
Lee et al[22] | 2013 | Human | UCB | CD34+ | 2 × 105 | IV | 150-200 |
Kornblit et al[23] | 2013 | Dog (beagle) | BM | NC | 1.8-5.3 × 108/kg | IV | 50 mL |
Fortin et al[24] | 2013 | Mice (B6.SJL-PtrcaPep3b/BoyJ CD45.1) | BM | NC | 2 × 106 | IV | NR |
Carrancio et al[25] | 2013 | Human | UCB | CD34+ | 1 × 105 | IV; IB | 200; 20 |
BM: Bone marrow; MNC: Mononuclear cells; NC: Nucleated cells; UCB: Umbilical cord blood; LSK: Lineage- Sca-1+ cKit+; IV: Intravenous; IB: Intrabone; NR: Not reported.